Journal Article10.1108/IJPHM-07-2013-0039
A consumer adoption model for personalized medicine: an exploratory study
Anja Hitz,Lea Prevel Katsanis +1 more
3
TL;DR: The results suggest that the most important factors leading to consumer adoption of PM are knowledge, relative advantage and compatibility with existing values.
read more
Abstract: Purpose – The purpose of this research is to identify factors linked to the potential acceptance of personalized medicine (PM) by consumers. Roger’s diffusion of innovation model (1995) and the work of Duguay et al. (2003) on transgenic biopharmaceuticals contributed to the development of the proposed conceptual model. Design/methodology/approach – The study design was an exploratory cross-sectional survey that used a Canadian national online panel of 307 respondents. Findings – The results suggest that the most important factors leading to consumer adoption of PM are knowledge, relative advantage and compatibility with existing values. The level of homophilus traits was negatively related to the acceptance of PM. Originality/value – Marketers will need to provide documented evidence of PM’s benefits over existing therapy based on improved efficacy and reduced side effects. Further, concerns about higher price, product distribution and drug reimbursement policies may limit its acceptance. This is the firs...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Genetic services diffusion in the precision medicine ecosystem
TL;DR: In this article, the authors identify GS diffusion drivers in the precision medicine (PM) ecosystem, using content analysis, the interviewees' visions were interplayed with the literature to achieve driver conceptualization, which posteriorly originated broad themes.
3
The Effect of Unethical practices in Pharmaceutical Personal Selling on Physicians Prescription Decision: A Comparative Analysis based on Medical Representatives' and Physicians' Perspectives
Sh. M. Fakhre Alam Siddiqui,Danish Ahmed Siddiqui +1 more
- 01 Jan 2024
Understanding ethical/unethical behavior in pharmaceutical companies: a literature review
TL;DR: In this paper, the authors examined and reviewed the available literature on ethical/unethical behavior of pharmaceutical companies and to determine the ethical issues, unethical behaviour by analysing, summarising and categorising the factors related to these issues and unethical behaviour as were studied during the period 2008-2017.
References
Welcome to the genomic era.
TL;DR: This issue of the Journal includes the last installment in a monthly series on genomic medicine that has focused on the ways in which the rapidly appearing tools of genomics have already begun to change the practice of medicine.
New medicines in primary care: a review of influences on general practitioner prescribing.
TL;DR: Focussing on new medicines, the determinants of uptake, the causes of geographical variations, and the influence of price, cost and financial incentives on prescribing behaviour are explored.
Population Screening in the Age of Genomic Medicine
TL;DR: Clinical benefit can be derived from screening adults for genes associated with classic inherited conditions, such as cystic fibrosis and Tay–Sachs disease, but also for genes that are better considered risk factors for complex diseases,such as factor V Leiden and mutations associated with hereditary hemochromatosis.
The Predictive Capacity of Personal Genome Sequencing
Nicholas J. Roberts,Joshua T. Vogelstein,Giovanni Parmigiani,Kenneth W. Kinzler,Bert Vogelstein,Victor E. Velculescu +5 more
TL;DR: An unbiased assessment of the capacity of whole-genome sequencing to provide clinically relevant information assuming that future research will allow us to understand the significance of every genetic variant is presented.
Pharmacogenetics, race, and ethnicity: social identities and individualized medical care.
TL;DR: The need for greater caution in using social categories as indicators for specific tests or therapies and for federal legislation to protect against discriminatory uses of individuals' genetic information is suggested.